Anne Irene Hagen

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Per Eystein Lønning, Jürgen Geisler, Lars Erik Krag et al. · Journal of Clinical Oncology · 2005 · 294 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients

Monica Jernberg Engstrøm, Signe Opdahl, Anne Irene Hagen et al. · Breast Cancer Research and Treatment · 2013 · 240 citations · Full text

Medicine, Oncology, Pathology +17

Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series

Anne Irene Hagen, Kjell Arne Kvistad, Marit Muri Holmen et al. · The Breast · 2007 · 176 citations

Medicine, Oncology, Radiology +16

Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers

Pål Møller, Anne Irene Hagen, Jaran Apold et al. · European Journal of Cancer · 2007 · 121 citations

Life Sciences, Genetics, Molecular Genetics +14

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study

Jürgen Geisler, Per Eystein Lønning, Lars Erik Krag et al. · European Journal of Cancer · 2006 · 100 citations

Medicine, Endocrinology, Oncology +16